nCap Medical LLC announced today that it will conduct clinical trials of its non-invasive, nanotechnology based, non-invasive product to mitigate both acute and chronic pain without the use of opioids.
Analysis of limited anecdotal evidence has suggested to the nCap Medical team to move into a clinical trial phase.
Dr. Joseph Shumway, the Company’s teaming partner in Qatar, will conduct random, double blind studies at the Sidra Academic and Research Hospital, Qatar. The Hospital receives support through the Qatar Ministry of Health and its other partner institutions at Education City, Qatar (Georgetown University, Carnegie Mellon University, Weill-Cornell Medicine in Qatar, College of the North Atlantic and HEC, Paris).
Dr. Joseph Shumway, MD, MPH, FACOG, Senior Consultant, Hamad Medical Corporation; Senior Attending Physician, Weill Cornell Medical College Academic Faculty, Qatar, will manage the study in Qatar.
Dr. Shumway will collaborate with Dr. G. Russel Reiss, MD, Cardiothoracic Surgery, nCap’s Chief Medical Officer, who will oversee US based clinical trials, in parallel.
nCap Medical LLC, is a member of the nCap group of companies consisting of, nCap Telecommunications LLC, nCap Energy LLC and nCap Licensing LLC. The nCap group of companies are manufacturers of products that utilize patented, nanotechnology based sensors to enhance performance and add functionality to diverse product applications. The companies have been selling their products, exclusively, to the US Military, law enforcement and US intelligence gathering agencies.
Upon successful completion of clinical trials, nCap Medical intends to add new manufacturing and research facilities at its Heber City factory.
Dr. Shumway is a minority owner of a membership interest in nCap Medical LLC
For further information, please contact:
nCap Technologies: 801-566-4124 firstname.lastname@example.org
Distributed by In2town Public Relations
Company Name: nCap Technologies
Contact Person: Media Manager
City: Heber City
Country: United States